Study drug after chemoradiation for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether giving the study drug becotatug vedotin after standard radiation and chemotherapy can help prevent nasopharyngeal cancer from coming back in people who are at high risk. It aims to see if this additional treatment improves outcomes without causing too many side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of nasopharyngeal cancer called non-keratinizing (WHO type II or III) that is considered high-risk and has spread to lymph nodes or nearby areas.
- You have completed all planned radiation and chemotherapy, including any induction chemo, and it’s been no more than 6 weeks since your last radiation session.
- Your blood counts, liver, kidney, and other organ functions are within acceptable levels (e.g., adequate white blood cells, hemoglobin, platelets, and no serious liver or kidney problems).
- You are able to care for yourself (ECOG performance status 0 or 1) and do not have a serious active infection or other uncontrolled medical conditions.
- Women who could become pregnant and men with partners who could become pregnant must agree to use effective birth control during treatment and for one year after the last dose of the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial tests whether adding an extra treatment after standard chemoradiation can reduce the chance of nasopharyngeal cancer coming back. The new treatment combines an immunotherapy drug (sintilimab) with a chemotherapy pill (capecitabine) for a year.
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
This trial studies a drug called MRG003 combined with another therapy that boosts the immune system to fight cancer. It aims to see if this combination can shrink tumors or slow the growth of nasopharyngeal cancer that has returned or spread.
This study tests a new combination for people whose nasopharyngeal cancer has returned in the same area and cannot be removed by surgery. The treatment combines a targeted drug (becotatug vedotin), an immunotherapy (PD-1 antibody), and radiation to try to shrink or control the cancer.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.